CareDx Inc. (NASDAQ:CDNA)’s share price fell 2.3% on Tuesday . The stock traded as low as $4.62 and last traded at $4.62, with a volume of 55,111 shares traded. The stock had previously closed at $4.73.

Several research firms have recently weighed in on CDNA. Leerink Swann reissued a “buy” rating on shares of CareDx in a research note on Tuesday, June 14th. Piper Jaffray Cos. reissued an “overweight” rating and issued a $6.00 price target (down from $8.00) on shares of CareDx in a research note on Thursday, April 21st. Zacks Investment Research downgraded shares of CareDx from a “hold” rating to a “sell” rating in a research note on Tuesday, April 12th. Finally, Mizuho lifted their target price on shares of CareDx from $8.00 to $12.00 and gave the stock a “buy” rating in a research note on Tuesday, June 14th. One research analyst has rated the stock with a hold rating and six have issued a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus target price of $9.25.

The company has a 50-day moving average price of $4.87 and a 200 day moving average price of $4.82. The stock’s market cap is $64.50 million.

CareDx (NASDAQ:CDNA) last posted its quarterly earnings results on Friday, May 6th. The company reported ($0.37) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.31) by $0.06. The firm had revenue of $6.60 million for the quarter, compared to analyst estimates of $6.97 million. During the same quarter in the previous year, the business posted ($0.19) earnings per share. The firm’s revenue for the quarter was down 8.3% on a year-over-year basis. On average, analysts predict that CareDx Inc. will post ($1.03) EPS for the current fiscal year.

CareDx, Inc, formerly XDx, Inc is a commercial-stage company, which develops, markets and delivers a diagnostic surveillance solution for heart transplant recipients. The Company’s commercialized testing solution, the AlloMap heart transplant molecular test or AlloMap, is a non-invasive blood-based test used to monitor heart transplant recipients for acute cellular rejection.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.